Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise
The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our...
324 Views
Mankind Pharma - Improvising the Base; Adding New Avenues for Growth
Following our Initiating Coverage on Mankind Pharma (MANKIND), we have highlighted certain key aspects from the recently released annual report.
345 Views
Mankind Pharma: Bharat Serum Acquisition to Be EPS Accretive from FY28
Mankind Pharma (Mankind) has entered into a definitive agreement to acquire a 100% stake in Bharat Serum and Vaccines (BSV) from Advent...
357 Views
Pharma and Healthcare (Q1FY25E Results Preview): Start the Year on a Strong Nod
The India Pharma & Healthcare sector is expected to maintain the growth momentum in Q1FY25E. We expect our coverage universe to see 11%/13% YoY...
322 Views
Mankind Pharma - Disruptor with a Dose of Care
In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic formulation (DF) franchise and become the fourth largest player by...
188 Views